The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken by the EU 27 Member States in the margins of the General Affairs Council (Art. 50). The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.
Read more ...
EU-US mutual recognition of inspections of medicines manufacturers enters operational phase
1 November 2017 marks the coming into operation of further aspects of the mutual recognition agreement between the European Union (EU) and the United States (US) to recognise inspections of manufacturing sites for human medicines conducted in their respective territories. This agreement, which updates the agreement from 1998, allows for recognition of each other's inspection outcomes and hence for better use of inspection expertise and resources.
Read more ...
New action plan to foster development of advanced therapies
The European Commission's Directorate-General for Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA) have published a joint action plan to foster the development of advanced therapy medicinal products (ATMPs). The main aim is to streamline procedures and better address the specific requirements of ATMP developers.
Read more ...
Countdown to launch of new EudraVigilance System
On 22 November 2017, the European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new system will have enhanced features for the reporting and analysis of suspected adverse reactions to support a better safety monitoring of medicines and a more efficient reporting process for stakeholders.
Read more ...
EMA publishes comments on Member States' hosting bids
The European Medicines Agency (EMA) has published the information it submitted to the European Commission in support of its assessment of the 19 Member States' bids to host the Agency. This decision comes following the recent publication of isolated pieces of information circulating in the press in order to complete the picture and set the record straight.
Read more ...
How the EU regulates medicines
The European Medicines Agency (EMA) will host an awareness session to present the European Union’s (EU) medicines regulatory system and EMA's role in it to international regulators and non-governmental organisations. A clear understanding of how medicines are regulated in different parts of the word is of prime importance in an increasingly globalised world where regulators rely on close cooperation.
Read more ...
EMA launches survey to assess whether patients and doctors are aware of the arrangements for reporting of side effects
The European Medicines Agency (EMA) has launched a survey to better understand patients’ and healthcare professionals’ awareness of reporting adverse drug reactions, including for medicines under ‘additional monitoring’. Medicines under additional monitoring are monitored particularly closely by regulatory authorities.
Read more ...